Boston Cell Standards

Boston Cell Standards is a pioneering diagnostics company addressing a critical quality gap in immunohistochemistry (IHC), a cornerstone technique for cancer diagnosis and therapy selection. The company's core innovation is a platform of IHCalibrators® and IHControls® that introduce quantitative, traceable standards and statistical process control to IHC, aiming to reduce diagnostic error rates from 10-30% to below 1%. Backed by significant non-dilutive funding from the National Cancer Institute and holding the first FDA clearance for quantitative IHC controls in breast cancer, BCS is positioned to transform IHC from a qualitative art into a calibrated, quantitative clinical assay. Its solutions serve both clinical diagnostic labs and pharmaceutical companies engaged in drug development.

Quantitative calibration (IHCalibrators®) and control (IHControls®) standards for Immunohistochemistry (IHC). The platform uses stable cell lines with defined antigen expression levels, traceable to NIST references, to enable statistical process control and objective measurement of IHC assay performance.

BCS is a first-mover in providing traceable, quantitative standards for IHC. Traditional competitors are large diagnostics companies (e.g., Roche, Agilent) that sell IHC reagents and scanners, but they have not historically offered standalone calibration/control systems. BCS's unique IP, NIST collaboration, and FDA clearance create significant barriers to entry and a differentiated position.